The international COMPASS project proposes that adding direct functional testing of drug sensitivities of patient-derived (PD) cancer cells to molecular profiling will provide additional key information for precision pediatric oncology.The COMPASS consortium has four main aims: I) establish a standardized ex vivo drug response profiling platform to discover unexpected drug efficacies and drug re-positioning opportunities, II) discover new biomarkers and molecular mechanisms for the drug efficacies seen, III) generate a large-scale online data resource of drug efficacies with integrated omics data providing a basis for novel precision therapies for incurable pediatric tumors and IV) clinical translation.
To achieve a high concordance in a multi-center setting, we will share standard operating procedures (SOP), a core set of genetically defined pediatric PD tumor models and a COMPASS core library containing clinically approved drugs.Within the framework of the current project, Single-cell Technologies LLC provides software solutions for automatic, intelligent image analysis methods, involving automatic software development for analyzing image based 3D modeling, and the implementation of single cell technology.